Genomics England is selecting companies with advanced capabilities to provide clinical interpretation for the 100K Genomes Project. NextCODE Health received top marks for its analytical capabilities across all the categories evaluated: Rare disease interpretation, secondary pipeline analysis, and cancer interpretation.

1. Global
Projects
Move
Genomic
Medicine
to
the
Next
Level
Hannes
Smarason
Genome
Sequencing
|Personalized
Medicine
|
Transforming
Health
Care

2. The
Next
Level
in
Genomic
Medicine
New
genomics-­‐based
technologies
and
tools
are
making
their
way
into
a
range
of
exci@ng
research
programs
and
clinical
studies
around
the
world.
Leading-­‐edge
organiza@ons
are
quickly
adop@ng
hardware
for
sequencing
and
systems
for
collec@ng
genomic
data.
Now,
the
focus
has
turned
to
analysis
and
interpreta@on
–
the
cri@cal
component
necessary
to
gain
the
insights
from
the
sequence
data
that
will
transform
medicine.

3. Global
Projects
Employing
Sequencing
• Earlier
this
year,
Genomics
England
announced
investments
for
broad
sequencing
and
analysis
of
100,000
human
genomes.
• At
the
@me,
Genomics
England
had
selected
Illumina
as
its
sequencing
partner
and
was
coordina@ng
resources
and
centers
to
support
the
effort,
including
resourcing
for
analysis
and
interpreta@on.
[See
blog
post
here.]
• Other
ini@a@ves,
such
as
the
Qatar
genomics
program
and
the
ini@a@ves
by
Longevity
and
Regeneron
also
represent
the
accelerated
progress
in
seeking
medical
advancements
from
genomic
data
insights.
[See
blog
post
here.]

4. Genomics
England
Turns
to
Data
Analysis
• This
week,
Genomics
England
announced
a
select
group
of
companies
with
advanced
capabili@es
to
move
to
the
next
stage
of
evalua@on
to
provide
clinical
interpreta@on
for
the
100K
Genomes
Project.
• At
the
@p
top
was
NextCODE,
which
received
top
marks
by
Genomics
England
for
its
analy@cal
capabili@es
across
all
the
categories
evaluated:
rare
disease
interpreta@on,
secondary
pipeline
analysis
and
cancer
interpreta@on.
[See
release
here.]

5. NextCODE
Technology
on
Top
• The
company’s
advanced
Genomically-­‐Ordered
Rela@onal
database,
or
GOR,
combined
with
its
clinical
and
discovery
interfaces
offer
the
most
advanced
and
reliable
capabili@es
to
support
the
ambi@ous
tasks
undertaken
by
Genomics
England,
and
are
already
proven
at
popula@on
scale.
[Read
more
on
the
GOR
database
here.]

6. ExciFng
Times
Ahead
The
coming
months
will
be
a
very
exci@ng
@me
for
genomic
medicine,
with
interpreta@on
taking
the
spotlight
as
we
take
leaps
toward
the
next
stage
of
personalized
medicine.
Read
more
about
NextCODE’s
work
here.